Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
This month, Nature Reviews Neurology launches a Series to highlight the importance of diversity, equity and inclusion in the neurology community and in neurological care to address health disparities and thereby to improve global brain health.
Nature Reviews Neurology is interviewing individuals who are driving efforts to address disparities in neurology through a broad spectrum of diversity, equity and inclusion initiatives. We spoke with stroke neurologist Nirali Vora from the USA about her work to build neurology capacity in low and middle-income countries.
A new study has found evidence of α-synuclein aggregates — a key pathological hallmark of Parkinson disease — in the gut and brain in people and animals with inflammatory bowel disease.
A study now reveals that CSF, but not imaging, biomarkers for Alzheimer disease show weaker correlation to cognitive measures in Black people than in White people. The findings offer insights into Alzheimer disease biomarker utility across racially diverse groups.
Though the burden of stroke has declined, it has grown rapidly in low-income and middle-income countries, and disparities still exist within high-income countries. In this Review, the authors highlight under-acknowledged disparities in the burden of stroke and review strategies for addressing key inequalities.
In this Review, Hamilton dissects the importance of racial and ethnic diversity among the neurology workforce for providing inclusive and equitable care to diverse populations. The Review summarizes current barriers to achieving diversity in the field and presents strategic approaches to overcoming these.
Recent clinical trials have highlighted the need for Alzheimer disease (AD) staging rather than simply noting the presence or absence of AD pathology. This article reviews current biomarker-based AD staging systems and outlines hypothetical frameworks to stage AD severity using fluid biomarkers.
Alzheimer disease is a complex and multifactorial condition. The authors of this Perspective suggest that its lack of a singular common pathogenesis prevents it from being regarded as a straightforward ‘disease’ and that treatment will therefore require a multifaceted approach.